Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX and SBRT in Locally Advanced Pancreatic Cancer
NCT07173387Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NALIRIFOX in pancreatic cancer (PC), sponsored by Shandong Cancer Hospital. Started Oct 2025; status: recruiting.
02
Drugs
NALIRIFOX
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07173387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173387.